LAS VEGAS — Cost and access to GLP-1s remains a challenge, but the benefits of these drugs aren't in doubt.

A new study from CVS Health aims to quantify at what price a GLP-1 drug has generated enough savings elsewhere through improved clinical outcomes. The healthcare giant used anonymized claims data from Aetna members in fully insured looks and found savings from reduced hospital and medical spending, as well as improved health outcomes.

But those benefits weren't enough to offset the increased pharmaceutical spending at the current price point, the study found.

The study tracked a mix of members who took GLP-1s from 2023 to 2025, so some patients had three years of follow-up care and management.

Industry observers note that amy Compton-Phillips, M.D., chief medical officer at CVS, told Fierce Healthcare that part of the challenge in this equation is that these drugs gained steam as a treatment for obesity at a high price. And while those costs have come down, the reductions haven't yet been enough to offset the expenditures.

In a recent development, another challenge for employers in particular — where GLP-1 coverage has been most in flux — is turnover, she stated. While GLP-1s do drive significant improvements, an employer may not reap the benefit of the reduced cost if an employee moves to a different company before those are realized, even though they paid for the medication initially.

The study sought to identify a price point where those savings would be felt, and landed at $350 per month over a three-year period. Achieving that, Compton-Phillips noted, would likely lure employers into embracing broader GLP-1 coverage.

"For them, it might be really worthwhile to say, 'Hey, at this price point I can afford to cover this for my employees, knowing that in the near term the savings will pay for my investment,'" she said.

In a recent development, the study found obesity rates declining after a 2022 peak, as well as a reduction of between 34% and 42% in hospitalizations over three years. Patients also had 14% lower odds of a serious cardiac event.

For patients who remained on the drugs for three years, their total medical spending decreased by $9,400, but associated pharmacy spend increased in tandem by $13,300, the study found.

Clinical improvements also fell off when patients were not able to remain adherent to the medication over several years, highlighting the importance of a wraparound approach that supports broader care management rather than simply prescribing a patient a GLP-1.

According to recent reports, compton-Phillips said CVS' own weight management program brings nutrition, peer coaching and other supports into the fold, in addition to the prescription. This is especially critical, she said, as evidence suggests weight gain is common after a patient stops taking their GLP-1, making behavior change key.

"At the moment, there's not great evidence that if you come off the drugs you will maintain the weight loss," she said.

Recent findings suggest that the CVS researchers stated the ultimate goal of the study was not to demand that all GLP-1 prescriptions repay their own costs, but to ensure that drug costs align with patient benefits and the broader cost of access. By lowering the net price of these products, more people can access them, the study concludes.

According to recent reports, "These drugs make people's lives better, and I want to give them out," Compton-Phillips remarked. Doing so becomes a challenge, though, "at the price they are today," she said.

→ Read original article